Cardio Diagnostics Holdings, Inc. Stock-Based Compensation
Cardio Diagnostics Holdings, Inc. (CDIO) reported Stock-Based Compensation of $49.09 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-07
- Cardio Diagnostics Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $24.35K, a 20.88% decline year-over-year.
- Cardio Diagnostics Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $24.73K, a 19.20% decline year-over-year.
- Cardio Diagnostics Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $24.08K, a 7.44% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $24.76K, a 9.48% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $110.23K, a 95.75% decline from fiscal 2024.
- Cardio Diagnostics Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $2.59M, a 102.55% increase from fiscal 2023.
- Cardio Diagnostics Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.28M.
- Cardio Diagnostics Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $49.09K 10-Q · filed 2026-08-07 | $73.17K derived: sum of 3 quarters · filed 2026-08-07 | $97.93K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $24.73K 10-Q · filed 2026-05-15 | $48.82K derived: sum of 2 quarters · filed 2026-05-15 | $73.58K derived: sum of 3 quarters · filed 2026-05-15 | $104.36K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $24.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $48.84K derived: sum of 2 quarters · filed 2026-03-13 | $79.62K derived: sum of 3 quarters · filed 2026-08-07 | $110.23K 10-K · filed 2026-03-13 |
| 2025-09-30 | $24.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $55.54K derived: sum of 2 quarters · filed 2026-08-07 | $86.15K 10-Q · filed 2025-11-12 | $108.57K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $30.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $61.39K 10-Q · filed 2026-08-07 | $83.81K derived: sum of 3 quarters · filed 2026-08-07 | $106.42K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $30.61K 10-Q · filed 2026-05-15 | $53.03K derived: sum of 2 quarters · filed 2026-05-15 | $75.64K derived: sum of 3 quarters · filed 2026-05-15 | $102.38K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $22.41K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $45.03K derived: sum of 2 quarters · filed 2026-03-13 | $71.76K derived: sum of 3 quarters · filed 2026-03-13 | $2.59M 10-K · filed 2026-03-13 |
| 2024-09-30 | $22.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $49.35K derived: sum of 2 quarters · filed 2025-11-12 | $2.57M 10-Q · filed 2025-11-12 | $2.63M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $26.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.55M 10-Q · filed 2025-08-14 | $2.61M derived: sum of 3 quarters · filed 2025-08-14 | $2.68M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.52M 10-Q · filed 2025-05-15 | $2.58M derived: sum of 2 quarters · filed 2025-05-15 | $2.65M derived: sum of 3 quarters · filed 2025-05-15 | $3.79M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $134.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.28M derived: sum of 3 quarters · filed 2025-03-20 | $1.28M 10-K · filed 2025-03-20 |
| 2023-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.21M derived: sum of 2 quarters · filed 2024-11-13 | $1.22M 10-Q · filed 2024-11-13 | $1.22M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.15M 10-Q · filed 2024-08-12 | $1.15M derived: sum of 3 quarters · filed 2024-08-12 | $1.15M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $4.00K 10-Q · filed 2024-05-15 | $4.00K derived: sum of 2 quarters · filed 2024-05-15 | $4.00K derived: sum of 3 quarters · filed 2024-05-15 | $4.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 derived: sum of 3 quarters · filed 2023-11-13 | $0.00 10-K · filed 2023-03-31 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $60.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |